Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
Summary
All studies
Exclusions
Mortality
Ventilation
ICU
Hospitalization
Serious outcomes
Recovery
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Favipiravir  COVID-19 treatment studies for Favipiravir  C19 studies: Favipiravir  Favipiravir   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) Nigella Sativa (meta)
Bromhexine (meta) Nitazoxanide (meta)
Budesonide (meta) Paxlovid (meta)
Casirivimab/i.. (meta) Povidone-Iod.. (meta)
Colchicine (meta) Probiotics (meta)
Conv. Plasma (meta) Proxalutamide (meta)
Curcumin (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychloro.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Outcomes in COVID-19 favipiravir studies
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ All studies 34% 18 4,288 Improvement, Studies, Patients Relative Risk, 95% CI With exclusions 34% 16 3,978 Mortality -8% 7 2,998 Ventilation -41% 3 1,226 ICU admission -29% 4 1,452 Hospitalization 23% 3 377 Progression 57% 2 149 Recovery 19% 9 1,602 Viral clearance 42% 8 909 RCTs 25% 10 2,164 Peer-reviewed 39% 14 3,418 Early 51% 4 467 Late 29% 14 3,821 Favipiravir for COVID-19 c19favipiravir.com Dec 3, 2021 Favors favipiravir Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ruzhentsova (RCT) 6% 0.94 [0.78-1.14] hosp. 3/112 2/56 Improvement, RR [CI] Treatment Control Udwadia (RCT) 40% 0.60 [0.38-0.95] recov. time 75 (n) 75 (n) Sawanpanyalert 68% 0.32 [0.15-0.66] progression n/a n/a Holubar (DB RCT) 89% 0.11 [0.01-2.02] hosp. 0/75 4/74 Tau​2 = 0.04; I​2 = 13.9% Early treatment 51% 0.49 [0.31-0.78] 3/262 6/205 51% improvement Cai 69% 0.31 [0.10-0.96] pneumonia 35 (n) 45 (n) Improvement, RR [CI] Treatment Control Ivashchenko (RCT) 46% 0.54 [0.33-0.88] viral+ 15/40 14/20 Pushkar (RCT) 14% 0.86 [0.74-0.99] no recov. 73/100 85/100 Solaymani-.. (RCT) -19% 1.19 [0.70-2.04] death 26/190 21/183 OT​1 Zhao (RCT) 59% 0.41 [0.18-0.93] viral+ 7/36 9/19 Aghajani 26% 0.74 [0.43-1.27] death 40 (n) 951 (n) Almoosa -42% 1.42 [0.90-2.25] death 33/110 24/116 Shinkai (SB RCT) 37% 0.63 [0.40-0.98] imp. time 107 (n) 49 (n) Assiri -79% 1.79 [0.33-8.02] death 11/67 3/51 Kulzhanova 88% 0.12 [0.04-0.37] no improv. 3/40 25/40 Alotaibi 57% 0.43 [0.18-1.01] death 244 (n) 193 (n) OT​1 Damayanti 54% 0.46 [0.22-0.92] no recov. 96 (n) 96 (n) Shenoy (DB RCT) -29% 1.29 [0.60-2.77] death 14/175 11/178 Chuah (RCT) -1154% 12.54 [0.76-208] death 5/250 0/250 Tau​2 = 0.15; I​2 = 68.3% Late treatment 29% 0.71 [0.54-0.93] 187/1,530 192/2,291 29% improvement All studies 34% 0.66 [0.52-0.85] 190/1,792 198/2,496 34% improvement 18 favipiravir COVID-19 studies c19favipiravir.com Dec 3, 2021 1 OT: comparison with other treatmentTau​2 = 0.14; I​2 = 65.8%; Z = 3.21 Effect extraction pre-specified Favors favipiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ruzhentsova (RCT) 6% 0.94 [0.78-1.14] hosp. 3/112 2/56 Improvement, RR [CI] Treatment Control Udwadia (RCT) 40% 0.60 [0.38-0.95] recov. time 75 (n) 75 (n) Sawanpanyalert 68% 0.32 [0.15-0.66] progression n/a n/a Holubar (DB RCT) 89% 0.11 [0.01-2.02] hosp. 0/75 4/74 Tau​2 = 0.04; I​2 = 13.9% Early treatment 51% 0.49 [0.31-0.78] 3/262 6/205 51% improvement Cai 69% 0.31 [0.10-0.96] pneumonia 35 (n) 45 (n) Improvement, RR [CI] Treatment Control Ivashchenko (RCT) 46% 0.54 [0.33-0.88] viral+ 15/40 14/20 Pushkar (RCT) 14% 0.86 [0.74-0.99] no recov. 73/100 85/100 Solaymani-.. (RCT) -19% 1.19 [0.70-2.04] death 26/190 21/183 OT​1 Zhao (RCT) 59% 0.41 [0.18-0.93] viral+ 7/36 9/19 Aghajani 26% 0.74 [0.43-1.27] death 40 (n) 951 (n) Almoosa -42% 1.42 [0.90-2.25] death 33/110 24/116 Shinkai (SB RCT) 37% 0.63 [0.40-0.98] imp. time 107 (n) 49 (n) Kulzhanova 88% 0.12 [0.04-0.37] no improv. 3/40 25/40 Alotaibi 57% 0.43 [0.18-1.01] death 244 (n) 193 (n) OT​1 Shenoy (DB RCT) -29% 1.29 [0.60-2.77] death 14/175 11/178 Chuah (RCT) -1154% 12.54 [0.76-208] death 5/250 0/250 Tau​2 = 0.15; I​2 = 70.1% Late treatment 29% 0.71 [0.53-0.95] 176/1,367 189/2,144 29% improvement All studies 34% 0.66 [0.50-0.86] 179/1,629 195/2,349 34% improvement 16 favipiravir COVID-19 studies after exclusions c19favipiravir.com Dec 3, 2021 1 OT: comparison with other treatmentTau​2 = 0.14; I​2 = 67.1%; Z = 3.12 Effect extraction pre-specified Favors favipiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Solaymani-.. (RCT) -19% 1.19 [0.70-2.04] 26/190 21/183 OT​1 Improvement, RR [CI] Treatment Control Aghajani 26% 0.74 [0.43-1.27] 40 (n) 951 (n) Almoosa -42% 1.42 [0.90-2.25] 33/110 24/116 Assiri -79% 1.79 [0.33-8.02] 11/67 3/51 Alotaibi 57% 0.43 [0.18-1.01] 244 (n) 193 (n) OT​1 Shenoy (DB RCT) -29% 1.29 [0.60-2.77] 14/175 11/178 Chuah (RCT) -1154% 12.54 [0.76-208] 5/250 0/250 Tau​2 = 0.12; I​2 = 48.2% Late treatment -8% 1.08 [0.73-1.59] 89/1,076 59/1,922 -8% improvement All studies -8% 1.08 [0.73-1.59] 89/1,076 59/1,922 -8% improvement 7 favipiravir COVID-19 mortality results c19favipiravir.com Dec 3, 2021 1 OT: comparison with other treatmentTau​2 = 0.12; I​2 = 48.2%; Z = 0.37 Favors favipiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Solaymani-.. (RCT) -53% 1.53 [0.86-2.71] 27/190 17/183 OT​1 Improvement, RR [CI] Treatment Control Shenoy (DB RCT) -33% 1.33 [0.67-2.66] 17/175 13/178 Chuah (RCT) -20% 1.20 [0.36-3.97] 6/250 5/250 Tau​2 = 0.00; I​2 = 0.0% Late treatment -41% 1.41 [0.93-2.13] 50/615 35/611 -41% improvement All studies -41% 1.41 [0.93-2.13] 50/615 35/611 -41% improvement 3 favipiravir COVID-19 mechanical ventilation results c19favipiravir.com Dec 3, 2021 1 OT: comparison with other treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 1.64 Favors favipiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Solaymani-.. (RCT) -19% 1.19 [0.73-1.94] 31/190 25/183 OT​1 Improvement, RR [CI] Treatment Control Almoosa -90% 1.90 [1.11-3.26] 110 (n) 116 (n) Shenoy (DB RCT) -2% 1.02 [0.57-1.82] 20/175 20/178 Chuah (RCT) -9% 1.09 [0.49-2.31] 13/250 12/250 Tau​2 = 0.00; I​2 = 0.0% Late treatment -29% 1.29 [0.97-1.72] 64/725 57/727 -29% improvement All studies -29% 1.29 [0.97-1.72] 64/725 57/727 -29% improvement 4 favipiravir COVID-19 ICU results c19favipiravir.com Dec 3, 2021 1 OT: comparison with other treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 1.75 Favors favipiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ruzhentsova (RCT) 6% 0.94 [0.78-1.14] hosp. 3/112 2/56 Improvement, RR [CI] Treatment Control Holubar (DB RCT) 89% 0.11 [0.01-2.02] hosp. 0/75 4/74 Tau​2 = 0.79; I​2 = 34.5% Early treatment 55% 0.45 [0.06-3.29] 3/187 6/130 55% improvement Ivashchenko (RCT) -300% 4.00 [0.20-79.6] hosp. 2/40 0/20 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Late treatment -300% 4.00 [0.20-79.6] 2/40 0/20 -300% improvement All studies 23% 0.77 [0.14-4.32] 5/227 6/150 23% improvement 3 favipiravir COVID-19 hospitalization results c19favipiravir.com Dec 3, 2021 Tau​2 = 0.76; I​2 = 31.8%; Z = 0.29 Favors favipiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ruzhentsova (RCT) 6% 0.94 [0.78-1.14] hosp. 3/112 2/56 Improvement, RR [CI] Treatment Control Sawanpanyalert 68% 0.32 [0.15-0.66] progression n/a n/a Holubar (DB RCT) 89% 0.11 [0.01-2.02] hosp. 0/75 4/74 Tau​2 = 0.00; I​2 = 0.0% Early treatment 65% 0.35 [0.18-0.69] 3/187 6/130 65% improvement Solaymani-.. (RCT) -19% 1.19 [0.70-2.04] death 26/190 21/183 OT​1 Improvement, RR [CI] Treatment Control Aghajani 26% 0.74 [0.43-1.27] death 40 (n) 951 (n) Almoosa -42% 1.42 [0.90-2.25] death 33/110 24/116 Assiri -79% 1.79 [0.33-8.02] death 11/67 3/51 Alotaibi 57% 0.43 [0.18-1.01] death 244 (n) 193 (n) OT​1 Shenoy (DB RCT) -29% 1.29 [0.60-2.77] death 14/175 11/178 Chuah (RCT) -1154% 12.54 [0.76-208] death 5/250 0/250 Tau​2 = 0.12; I​2 = 48.2% Late treatment -8% 1.08 [0.73-1.59] 89/1,076 59/1,922 -8% improvement All studies 11% 0.89 [0.57-1.37] 92/1,263 65/2,052 11% improvement 10 favipiravir COVID-19 serious outcomes c19favipiravir.com Dec 3, 2021 1 OT: comparison with other treatmentTau​2 = 0.24; I​2 = 60.5%; Z = 0.54 Effect extraction pre-specified Favors favipiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ruzhentsova (RCT) 39% 0.61 [0.43-0.88] no recov. 112 (n) 56 (n) Improvement, RR [CI] Treatment Control Udwadia (RCT) 40% 0.60 [0.38-0.95] recov. time 75 (n) 75 (n) Holubar (DB RCT) 16% 0.84 [0.54-1.29] no recov. 65 (n) 70 (n) Tau​2 = 0.00; I​2 = 0.0% Early treatment 33% 0.67 [0.53-0.85] 0/252 0/201 33% improvement Ivashchenko (RCT) -67% 1.67 [0.52-5.39] no disch. 10/40 3/20 Improvement, RR [CI] Treatment Control Pushkar (RCT) 14% 0.86 [0.74-0.99] no recov. 73/100 85/100 Almoosa -11% 1.11 [0.96-1.29] recov. time 110 (n) 116 (n) Shinkai (SB RCT) 37% 0.63 [0.40-0.98] imp. time 107 (n) 49 (n) Damayanti 54% 0.46 [0.22-0.92] no recov. 96 (n) 96 (n) Shenoy (DB RCT) -1% 1.01 [0.78-1.30] no recov. 157 (n) 158 (n) Tau​2 = 0.04; I​2 = 69.1% Late treatment 11% 0.89 [0.72-1.09] 83/610 88/539 11% improvement All studies 19% 0.81 [0.68-0.98] 83/862 88/740 19% improvement 9 favipiravir COVID-19 recovery results c19favipiravir.com Dec 3, 2021 Tau​2 = 0.04; I​2 = 67.7%; Z = 2.22 Favors favipiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ruzhentsova (RCT) 22% 0.78 [0.92-1.79] viral+ 112 (n) 56 (n) Improvement, RR [CI] Treatment Control Udwadia (RCT) 29% 0.71 [0.46-1.10] viral time 75 (n) 75 (n) Holubar (DB RCT) -32% 1.32 [0.83-2.08] viral+ 59 (n) 57 (n) Tau​2 = 0.05; I​2 = 54.1% Early treatment 11% 0.89 [0.63-1.26] 0/246 0/188 11% improvement Cai 71% 0.29 [0.10-0.86] viral+ 35 (n) 45 (n) Improvement, RR [CI] Treatment Control Ivashchenko (RCT) 46% 0.54 [0.33-0.88] viral+ 15/40 14/20 Pushkar (RCT) 90% 0.10 [0.02-0.40] viral+ 2/100 21/100 Zhao (RCT) 59% 0.41 [0.18-0.93] viral+ 7/36 9/19 Kulzhanova 50% 0.50 [0.21-1.20] viral+ 6/40 12/40 Tau​2 = 0.08; I​2 = 29.8% Late treatment 60% 0.40 [0.25-0.62] 30/251 56/224 60% improvement All studies 42% 0.58 [0.40-0.85] 30/497 56/412 42% improvement 8 favipiravir COVID-19 viral clearance results c19favipiravir.com Dec 3, 2021 Tau​2 = 0.17; I​2 = 66.9%; Z = 2.79 Favors favipiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ruzhentsova (RCT) 6% 0.94 [0.78-1.14] hosp. 3/112 2/56 Improvement, RR [CI] Treatment Control Udwadia (RCT) 40% 0.60 [0.38-0.95] recov. time 75 (n) 75 (n) Holubar (DB RCT) 89% 0.11 [0.01-2.02] hosp. 0/75 4/74 Tau​2 = 0.00; I​2 = 0.0% Early treatment 41% 0.59 [0.38-0.92] 3/262 6/205 41% improvement Ivashchenko (RCT) 46% 0.54 [0.33-0.88] viral+ 15/40 14/20 Improvement, RR [CI] Treatment Control Pushkar (RCT) 14% 0.86 [0.74-0.99] no recov. 73/100 85/100 Solaymani-.. (RCT) -19% 1.19 [0.70-2.04] death 26/190 21/183 OT​1 Zhao (RCT) 59% 0.41 [0.18-0.93] viral+ 7/36 9/19 Shinkai (SB RCT) 37% 0.63 [0.40-0.98] imp. time 107 (n) 49 (n) Shenoy (DB RCT) -29% 1.29 [0.60-2.77] death 14/175 11/178 Chuah (RCT) -1154% 12.54 [0.76-208] death 5/250 0/250 Tau​2 = 0.07; I​2 = 59.1% Late treatment 22% 0.78 [0.58-1.05] 140/898 140/799 22% improvement All studies 25% 0.75 [0.58-0.96] 143/1,160 146/1,004 25% improvement 10 favipiravir COVID-19 Randomized Controlled Trials c19favipiravir.com Dec 3, 2021 1 OT: comparison with other treatmentTau​2 = 0.06; I​2 = 50.3%; Z = 2.26 Effect extraction pre-specified Favors favipiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Solaymani-.. (RCT) -19% 1.19 [0.70-2.04] 26/190 21/183 OT​1 Improvement, RR [CI] Treatment Control Shenoy (DB RCT) -29% 1.29 [0.60-2.77] 14/175 11/178 Chuah (RCT) -1154% 12.54 [0.76-208] 5/250 0/250 Tau​2 = 0.05; I​2 = 18.7% Late treatment -33% 1.33 [0.78-2.26] 45/615 32/611 -33% improvement All studies -33% 1.33 [0.78-2.26] 45/615 32/611 -33% improvement 3 favipiravir COVID-19 RCT mortality results c19favipiravir.com Dec 3, 2021 1 OT: comparison with other treatmentTau​2 = 0.05; I​2 = 18.7%; Z = 1.05 Favors favipiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Udwadia (RCT) 40% 0.60 [0.38-0.95] recov. time 75 (n) 75 (n) Improvement, RR [CI] Treatment Control Sawanpanyalert 68% 0.32 [0.15-0.66] progression n/a n/a Tau​2 = 0.10; I​2 = 48.8% Early treatment 53% 0.47 [0.26-0.86] 0/75 0/75 53% improvement Cai 69% 0.31 [0.10-0.96] pneumonia 35 (n) 45 (n) Improvement, RR [CI] Treatment Control Ivashchenko (RCT) 46% 0.54 [0.33-0.88] viral+ 15/40 14/20 Solaymani-.. (RCT) -19% 1.19 [0.70-2.04] death 26/190 21/183 OT​1 Zhao (RCT) 59% 0.41 [0.18-0.93] viral+ 7/36 9/19 Aghajani 26% 0.74 [0.43-1.27] death 40 (n) 951 (n) Almoosa -42% 1.42 [0.90-2.25] death 33/110 24/116 Shinkai (SB RCT) 37% 0.63 [0.40-0.98] imp. time 107 (n) 49 (n) Assiri -79% 1.79 [0.33-8.02] death 11/67 3/51 Kulzhanova 88% 0.12 [0.04-0.37] no improv. 3/40 25/40 Alotaibi 57% 0.43 [0.18-1.01] death 244 (n) 193 (n) OT​1 Damayanti 54% 0.46 [0.22-0.92] no recov. 96 (n) 96 (n) Chuah (RCT) -1154% 12.54 [0.76-208] death 5/250 0/250 Tau​2 = 0.25; I​2 = 69.9% Late treatment 36% 0.64 [0.45-0.93] 100/1,255 96/2,013 36% improvement All studies 39% 0.61 [0.44-0.84] 100/1,330 96/2,088 39% improvement 14 favipiravir COVID-19 peer reviewed trials c19favipiravir.com Dec 3, 2021 1 OT: comparison with other treatmentTau​2 = 0.22; I​2 = 68.1%; Z = 3.04 Effect extraction pre-specified Favors favipiravir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ruzhentsova (RCT) 6% 0.94 [0.78-1.14] hosp. 3/112 2/56 Improvement, RR [CI] Treatment Control Ruzhentsova (RCT) 39% 0.61 [0.43-0.88] no recov. 112 (n) 56 (n) Ruzhentsova (RCT) 22% 0.78 [0.92-1.79] viral+ 112 (n) 56 (n) Udwadia (RCT) 40% 0.60 [0.38-0.95] recov. time 75 (n) 75 (n) Udwadia (RCT) 29% 0.71 [0.46-1.10] viral time 75 (n) 75 (n) Sawanpanyalert 68% 0.32 [0.15-0.66] progression n/a n/a Holubar (DB RCT) 89% 0.11 [0.01-2.02] hosp. 0/75 4/74 Holubar (DB RCT) 30% 0.70 [0.23-2.12] ER visit 5/75 7/74 Holubar (DB RCT) 16% 0.84 [0.54-1.29] no recov. 65 (n) 70 (n) Holubar (DB RCT) -32% 1.32 [0.83-2.08] viral+ 59 (n) 57 (n) Cai 69% 0.31 [0.10-0.96] pneumonia 35 (n) 45 (n) Cai 71% 0.29 [0.10-0.86] viral+ 35 (n) 45 (n) Ivashchenko (RCT) 46% 0.54 [0.33-0.88] viral+ 15/40 14/20 Ivashchenko (RCT) 62% 0.38 [0.09-1.52] viral+ 3/40 4/20 Ivashchenko (RCT) -67% 1.67 [0.52-5.39] no disch. 10/40 3/20 Ivashchenko (RCT) -300% 4.00 [0.20-79.6] hosp. 2/40 0/20 Pushkar (RCT) 14% 0.86 [0.74-0.99] no recov. 73/100 85/100 Pushkar (RCT) 33% 0.67 [0.54-0.82] recov. time 100 (n) 100 (n) Pushkar (RCT) 45% 0.55 [0.42-0.72] no recov. 40/100 73/100 Pushkar (RCT) 20% 0.80 [0.64-1.00] recov. time 100 (n) 100 (n) Pushkar (RCT) 70% 0.30 [0.16-0.58] no disch. 10/100 33/100 Pushkar (RCT) 27% 0.73 [0.63-0.86] no recov. 66/100 90/100 Pushkar (RCT) 33% 0.67 [0.50-0.89] pneumonia 40/100 60/100 Pushkar (RCT) 90% 0.10 [0.02-0.40] viral+ 2/100 21/100 Solaymani-.. (RCT) -19% 1.19 [0.70-2.04] death 26/190 21/183 OT​1 Solaymani-.. (RCT) -53% 1.53 [0.86-2.71] ventilation 27/190 17/183 OT​1 Solaymani-.. (RCT) -19% 1.19 [0.73-1.94] ICU 31/190 25/183 OT​1 Zhao (RCT) 59% 0.41 [0.18-0.93] viral+ 7/36 9/19 Zhao (RCT) 52% 0.48 [0.25-0.91] viral time 36 (n) 19 (n) Aghajani 26% 0.74 [0.43-1.27] death 40 (n) 951 (n) Almoosa -42% 1.42 [0.90-2.25] death 33/110 24/116 Almoosa -90% 1.90 [1.11-3.26] ICU 110 (n) 116 (n) Almoosa -11% 1.11 [0.96-1.29] recov. time 110 (n) 116 (n) Shinkai (SB RCT) 37% 0.63 [0.40-0.98] imp. time 107 (n) 49 (n) Shinkai (SB RCT) 59% 0.41 [0.18-0.93] imp. time 47 (n) 13 (n) Assiri -79% 1.79 [0.33-8.02] death 11/67 3/51 Kulzhanova 88% 0.12 [0.04-0.37] no improv. 3/40 25/40 Kulzhanova 89% 0.11 [0.01-2.00] no improv. 0/40 4/40 Kulzhanova 50% 0.50 [0.21-1.20] viral+ 6/40 12/40 Alotaibi 57% 0.43 [0.18-1.01] death 244 (n) 193 (n) OT​1 Damayanti 54% 0.46 [0.22-0.92] no recov. 96 (n) 96 (n) Shenoy (DB RCT) -29% 1.29 [0.60-2.77] death 14/175 11/178 Shenoy (DB RCT) -33% 1.33 [0.67-2.66] ventilation 17/175 13/178 Shenoy (DB RCT) -2% 1.02 [0.57-1.82] ICU 20/175 20/178 Shenoy (DB RCT) -1% 1.01 [0.78-1.30] no recov. 157 (n) 158 (n) Shenoy (DB RCT) 6% 0.94 [0.75-1.18] no recov. 175 (n)